<SEC-DOCUMENT>0001193125-11-350871.txt : 20111222
<SEC-HEADER>0001193125-11-350871.hdr.sgml : 20111222
<ACCEPTANCE-DATETIME>20111222170133
ACCESSION NUMBER:		0001193125-11-350871
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20111221
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20111222
DATE AS OF CHANGE:		20111222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPLIGEN CORP
		CENTRAL INDEX KEY:			0000730272
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				042729386
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14656
		FILM NUMBER:		111278111

	BUSINESS ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		7814499560

	MAIL ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d273367d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported) December&nbsp;21, 2011 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>REPLIGEN CORPORATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registration as specified in charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-14656</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>04-2729386</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>02453</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code (781)&nbsp;250-0111 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report.)
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Other Events</U>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
December&nbsp;21, 2011, Repligen Corporation issued a press release. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Financial Statements and Exhibits</U>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1 Press
Release by Repligen Corporation, dated December&nbsp;21, 2011. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">SIGNATURES </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">REPLIGEN CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: December&nbsp;22, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Walter C. Herlihy</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Walter C. Herlihy</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT INDEX </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:25pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release by Repligen Corporation, dated December 21, 2011.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d273367dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR>
<TD VALIGN="top">


<IMG SRC="g273367ex99_1pg001.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repligen Corporation</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">41
Seyon Street</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building #1, Suite 100</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Waltham, Massachusetts 02453</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Telephone:
781-250-0111</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Telefax:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;781-250-0115</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR IMMEDIATE RELEASE</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONTACT: </B></FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Walter C. Herlihy, PhD</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(781)
419-1900</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura L. Whitehouse</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">VP,
Market Development</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(781) 419-1812</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Repligen Announces Submission of New Drug Application for SecreFlo&#153; for Improved Pancreatic
Imaging In Patients with Pancreatitis </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WALTHAM, MA &#150; December&nbsp;21, 2011</B> &#150; Repligen Corporation (NASDAQ: RGEN)
announced today that it has submitted a New Drug Application (NDA) for SecreFlo&#153; (RG1068, synthetic human secretin) to improve detection of pancreatic duct abnormalities in combination with MRI in patients with pancreatitis. Structural
abnormalities of the pancreatic ducts are a common cause of pancreatitis and may result in significant abdominal pain. In the pivotal Phase 3 study, the addition of SecreFlo&#153; to an MRI led to highly statistically significant improvements in
sensitivity, image quality, ability to visualize the full length of the pancreatic ducts and diagnostic confidence when compared to MRI alone. A radiologist&#146;s ability to more confidently identify the presence or absence of pancreatic duct
abnormalities has the potential to improve patient triage and care. The SecreFlo&#153; NDA was filed with a request for priority review of the application which, if granted, would result in a 6 month review period. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;I would like to express my deep appreciation to our employees, clinical investigators and consultants for their dedication and hard work to
accomplish this pivotal milestone for the Company,&#148; stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. &#147;SecreFlo&#153; has the potential to be an important diagnostic tool to help radiologists and
gastroenterologists confidently plan the best course of treatment for their patients.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are very pleased to have filed
Repligen&#146;s first NDA and we look forward to continuing to work closely with the FDA to advance SecreFlo&#153; through the review process,&#148; stated Dr.&nbsp;Michael&nbsp;L. Hall, Chief Medical Officer at Repligen Corporation. &#147;We
currently expect to hear back from the FDA in 60 days if our application is accepted for review and whether FDA will grant the NDA priority review.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">SecreFlo&#153; has previously been granted Fast Track Designation based on the need to develop safer, non-invasive alternatives to diagnostic ERCP, an invasive endoscopic procedure used to diagnose and
treat diseases of the pancreas which is potentially harmful for patients. The product has also been granted Orphan Drug Designation which qualifies Repligen to receive seven years of marketing exclusivity in the United States if we are the first
company to obtain approval for SecreFlo&#153; in combination with MRI. There are more than 300,000 MRI procedures conducted in the U.S. and Europe each year that could directly benefit from the addition of SecreFlo&#153;. We plan to file a Marketing
Authorization Application in Europe next quarter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">SecreFlo&#153;, a synthetic version of the hormone secretin, stimulates secretion of watery
fluid into the pancreatic ducts. When the pancreatic ducts are filled with water they are more effectively visualized </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- more -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Repligen Announces Submission of New Drug Application for SecreFlo for Improved Pancreatic Imaging
in Patients with Pancreatitis, December 21, 2011 </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I> Page
 2
 of 2 </I></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
by MRI. The pivotal Phase 3 study was a multi-center, baseline controlled, single dose study in which 258 patients enrolled at 23 clinical sites within the U.S. and Canada received an MRI of the
pancreas with and without SecreFlo&#153;, and separately an ERCP. The MRI images were randomized and independently reviewed by three radiologists for evaluation of the presence or absence of 10 pre-specified pancreatic duct abnormalities, image
quality, visualization of the main pancreatic duct and confidence in diagnostic findings. The analysis of the Phase 3 radiographic images was a &#147;re-read&#148; which was agreed to by the Food and Drug Administration and European Medicines Agency
based on the determination that the original analysis was flawed and therefore inconclusive. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Pilot Study in Pancreatic Cancer
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A pilot study is currently being conducted to evaluate the ability of SecreFlo&#153; to improve detection and characterization of
pancreatic cancer in combination with contrast-enhanced MRI and computed tomography (CT). This study harnesses the second biologic property of SecreFlo&#153; to increase blood flow to the tissues of the pancreas. Early detection of pancreatic cancer
will increase the identification of patients who are candidates for surgery and may improve patient outcomes. We expect to release initial results from this study in the first half of 2012. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About Repligen Corporation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repligen Corporation is a leading supplier of critical
biological products used to manufacture biologic drugs.&nbsp;Repligen also applies its expertise in biologic product development to Secreflo&#153;, a hormone which is being developed as a novel imaging agent for the diagnosis of a variety of
pancreatic diseases. In addition, we have two early stage CNS rare disease programs which are advancing into Phase 1 clinical trials. Repligen&#146;s corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453.
Additional information may be requested at www.repligen.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This press release contains forward-looking statements which are made
pursuant to the safe harbor provisions of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute
guarantees of future performance. Investors are cautioned that express or implied statements in this press release which are not strictly historical statements, including, without limitation, statements regarding, our expectations for and the
potential timing of the FDA&#146;s review of and response to the NDA, and plans and objectives for product development, regulatory approval, and product sales constitute forward-looking statements. Such forward-looking statements are subject to a
number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the FDA&#146;s evaluation of and response to our NDA filing, our compliance with all
Food and Drug Administration and EMEA regulations, and other risks detailed in Repligen&#146;s filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press
release or with respect to the announcements described herein except as required by law. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- ### - </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g273367ex99_1pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g273367ex99_1pg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`(`"0`P$1``(1`0,1`?_$`&P```("`P$!````````
M``````@)!@<%"@L$`P$!`````````````````````!````<!``$$`@("`@$%
M`````0(#!`4&!P@)`!$2"B$3%!4Q(D$6%S(C0R@9$0$`````````````````
M````_]H`#`,!``(1`Q$`/P!CWV]^V]8Y3XMYWH>$ZI><@TW;N@%GJUJSFVS5
M,M8Y]EM,E7EDC6\S7GT?*),7EHN$`*Y2J`10J8%-[@/MZ!(G,7AZ^R+U3SSC
M/25*\FTY5Z9N.>5K3JE!WKLCJ.,MS.L6^/2EX`\['Q%.G(YH\>Q+E%Q^M)VN
M!2*E`3>_N``%]F[J\X7@A\@5.QOIKI_0=I"/<46[VK,K5K5CW3)=ER>VR3B.
M<&KKJ\I'GZY(218M\T;O$&\7*,9!I[B4Z(?%8.J-,6FO5NMO+?:9J+JE:BXP
M9B9G+-(LH*)A(U-$%UWDS)R2[=C&MFJ8^ZJBRA"$]A]Q]`$].\J'C5T+0&^5
MT?O3DFTZ$]?A$QU5A-[S5])2TJ97]!(N&!&Q&;S,DHM_H5!J=94Q_P#4"B(^
MWH#6MENJ="K<S<KU9Z]2ZA7&*TI8;7;)J-KE;@8QN`"O(S,[,.6<7%L4`$/F
MLNJFF7W_`"(>@H"4[<XTA<NF-OD^L>;VV-U^;&L3>I_^;<W6SZ,LX,6\F%8=
MVYO9%8)*R&CG:2Y8\5_Y9D52'!,2F*(AE^>NN^6NM(:5L',?0N.[U$P*Z+:?
M<Y3H-9NIX!PX_9_&1GFD'(NWL*HZ!$XI`Z32_:!1$GN`#Z#4*^XQWON/.3;B
M7">==JT[&K;;W6JZQ?)/*KU8J)./X"&3K-.I$=(OJQ(QL@\BWTE*3:@(*',B
M99F4WQ^1"B`,S[^QSH`O@NY_Y6C>ULLYPZ.NF>\SU>]="=9])RN,R,]8*S$0
M.A:L@QU-V,G:)6ZSMB@CI'03$RBD<HX`YRD*("%\>*RF_P#Y;^(X+]V9U73M
ML95!+4^@]2Z)J^JV/;,^E*M)2B@5A//[W8$TY:V,U*C#Q;1FU:I>SN77.@U(
MH=4HJ`H?*G/EC^R`YM&RP?0EX\7_`(IE+#8*ME-?S1LH7H'HJ*A7RT9(SDO8
M(R4A'BT>9XS,W>N/[(M>:/"J,FC&45;.GOH(UT7]:KH'AO+;[U3XQO)AUU#=
M!9)5Y_1W-/TBT,UV.K-JO%N9J;KR$M5$*_'$EI1@R4!JTFXR9CI!?X-G)D4U
M#+I@\_P(^2*Y>4/QXTK?=4CXMEL]-NEIQ7874$R2C(*QW6E,X*70M\5%(@"$
M26T5*U1;QTU2`K9"14<$0*1`J9"@SO9.C>?>=8EI/;_N60XC"OS*DCY36='J
M&>,I$Z`%%9..<6R8B4WZJ0&`3%1$YB@/Y#T&9R?:\<WJJIWG#]7S?8J6JX.S
M);,NN]:OM<_F)IIJJLC356DY2/(]136*)T3*`H0#!\BA[^@SKC0Z`TMR6?NK
MQ3VU\6B5)]&DN+-"HVY6"2!<59I*MJ/2S*D2F#543.01%$/UF]S?ZC[!2%-[
M;XUT71U,>S_K'FV\:PDNJU-FM1V_-;'>A=MP4%RT3JL197DTL[:@D?\`:D1$
MRB7Q'Y`'L/H.>I]T#;G>E>0CG'F^`_ERQ<4Y^:2BD2Q35=N?^_;A<Y%RYC6S
M%N"BRS]W5Z?7S$(4@G4_>4"@/N`>@O"F?:^[PY^QBE4&.\5M>JE`Q[.*K0H2
M4L*NX1\1"URCUMA6X563<NJNQ:HMFS",3^8&62#V`0^8?Y]!1OB4S!Y]C7RV
M7/M7NO:,T9S&#&H>EI\F5"%LC!_;J-G\E&LZ-7:TC*IOH:/Q2L6ARU"PJJRT
MC-R#M\9-5%(LC_-('G\^_DB<>1'RFMO'/9^F6W,/CZP'64<OU2\KEG']9D;O
M4#+*:]IMQ@:TB\>W63J<NR=U^JQ:A3LR/&I5_DW,]763`%?+/R;X&,CYFHMS
M\8/<%TVG?X2\0-=O.?7)W.32=VI,I#RO]K=&BCK)J"PKLS7YQ@T$4D5Q;+-G
MBA01^9"']`\GJ_N73I?Z<^`3>IV64EM0Z*EJKRVVLLX^5?3]GJ^;[G>EV\@\
M>NU#/I)R[R["P8NW*IE%G!CF44,8R@B(53X1_K1TGO#@K.][[GVK>H+-]`E;
MS<><\%R:R5^JP]8B9IVRK,IK]F6L56MR+RTZ">G("V20:MQ&%8L#KN'!%$F[
M4%Z>*K.[]XU?LVU?D3*-%F+=6J]T)J'.-KD4_9@71\C?52QR21;C$,5#L%)"
M#;M&$JX2+[I-9B+`Z?L"8>@*?S8&-Y!/M#<[\FMU1F*MG=OY/Y]EVI?FLT1@
M%)-KMVLK%2]C%_8PB+](IN!]O;W9>P_@OH"`^[-L[ZS['P5R373F=O8BHZ#L
M,G"-!$ZSZ4T>RPN<4(@HE-\?WI#1)E-$!#Y>SH?;\#^0)C['+*QXKPEX>O#/
MF$D6`5WFTXYDMJ+'?Z)R,3B$/EN<0C"123,"3J/E].T)G,*`(_\`N/(=,_O^
M!]!N1TFATKE#F^O9UE5*?K4/GO'FE=H]"JD<9W-R<%FU2!M$0$-'L4%%I.Q3
M2,25,@$3.L[>K?(0,<X^X:P^@?9*[JS"D6G0].^OKVE1,[IT(_G[C<;G9KE`
M56N5Y@B961E9^9EN:FT;'1C9`!%518Y4RE_R/H#CK/F?IT!X0+;Y<'?.$3A$
M:^A+L[RK#!LS&<0M]V+HCW&\V+(34'5J7\F-PNK%)9V9%E^]M#IJ*E,?X![`
MBWQ[XQX<^I*,T[K\V7?/,'5';W1[`;K-9QKG5]<K%.YSJ,TH=U5<NA\[@K_7
M`B9N%A5$Q>,71`9PBJG\%JT1.V5<N@D'B^3Y7Y)^R39.>O%_LU9T;ASI_D^;
MNUPJ.<ZA_P"6<VH]\K3&8L*,1'V1&9L`NI2K2U4`[,[QVX>,&%H6:?L$ARAZ
M#"-^4IOS)?9-\CJ$SIM\H7*?,=!J7/FX!F5C>5:UZ/5X5C6ZPZP!*V1OM*5N
MLZ+IE1L3N>4:*)K.8B.=,0,07@J$"&?92\5'#7!N.</Z3P'CA.=>H;)UM3<V
MHC[/[A>G+Z?:!79N<8RSE*Q6:<7-9:M>8N".SE$#)O"J.S%4.I\T_P!8`]4E
M4_(]]OX\TW6)9:;0.P'TTW=@8KF+3J7$5+,E"N$Q'W3&-E)[(&OP_P"#JO0_
MY-Z#HN=B:##Y-R1U%J5@9,9.#SGGC:+Q+1DF@BZCI./JN<V.;=QKYJX*=NY:
M2"+(45$U"B0Y3B4P"`CZ#G_?20R)2=Z\[*W4XA_'S7GFI9B0GS^(F>[#HC:R
MIJ`0!`#%2:8PL4?</8!4#V]`L+&)+E'AKSC=85SS%X`YU+('6D]%5VTQ]CI[
MRW!`V.ZZ"2[YYMS2LHNF<A9(*>A40.W7:"NJ>.G?Y*22HE`@@UJZ]K>%_<^I
M,MY;\4G@CR;N"Q7_`.#)U8[C&6+$F*,PZ>(D%>.AUJU;)=E2JS&"9U-SLV6(
M:LD_<?A^I,5SAD_M[2-.P[+_`!C^/'':%4,SJ])K&B["^R?,DW0TZ`DYM[#T
MRK,ZHT<-6T@ZCU;&M;A;K+))N'!EQ,<@'.8``QN.OM1\+\?^,;$L0N69;4GU
MUS)B%;PEY@1*0:%AIR_9;")TII(O+X]=ECJU7)=U$)NI0'*']Q'*J+HE8N%$
MBBJ`^_5PX>WCJ?M[;O-MU1".HN%DYW7)S*9J:CUXIMHNS[*]F$]'O-3;R/S,
M.?Y_6)N3BD7("+8[V1*BW5,>.=%(`V>`I-3OO[*O3'9+U()>O4B4ZNZ)AGRA
M?VM&C:[V=;(LU8IF,(A^QE5=&`6WM_@K'Y!_Z?0?/N3X>0[[=V78ZF49NFY)
MO."YHX:E$'"1JGS?6&>QZS&JA\3$30_[''6-%0I@]BB80'\^@=!]LSG_`&.'
MB."/)GCM6?79/Q^[6:RZ5!,DEW!8JMRUOS6ZU2Y2A&Z2JS6L1=PS=.-DG)2G
M_1_<(*&`$B*'(#>>>OL!^)+H+)J_J2/:F)9,ZDX9J_L&<;==X7,-%IDJ9`AY
M*ORU>M3F.4E7$6Z$R/\`+BS/F#H2_-NNJ0P"(:U/V)?.1$]A\=;#SGXZ(&YZ
MQS;&66A5_L#L>/K<S"91'IRMC9O:5B=!EYMK%/)^8N=EC$%I%TFD5-2-:F2;
M$=-G#AP@!*^=WD+1L:^L?RGB-!@91VWYC#DV<W)G%-5EEFL0PSVQP5YL,DW:
MIB?^N;ZY=6CMV<2?!$#BNH)2IF,`7QD-E^IE-\I4/>[%4/&I7F(9Y6W]IJ%M
MK="/MD+8T:ZR6G*S,96+=UI\Q;64@55%0K:-=_S5B_L0.NFH10X77X6)7E[2
M6'2?D+RKQ:\_\(<S49"[PO,F\Q%2:U?<-QQZ"+*RE[O<O"$@XYE5*4XB8!C\
M3-GCQ!T^%RW(L<K$ZJH5-]2.IS-UYG[;[DM[8R=Q[7[9T2WN'2P&,L]@:L09
M1-85C![JD3O6B6)+\"(`9(?^?01KS`__`&N^P?X1N*$?:5@<77LO7U\BB#^Q
MFFG%3;RYL`F$P_!0_A\XBB0#?Y+)`'_R>@V0<EX*XDP71W>PXGR5SKD^KOV\
MTT?:3GN/T6I7EVVL:Q'-@1<VB$A&<RLG-N"`=T!EA_D&#W/\A]`1]SIM2T6H
MV>@7ZM0=SH]U@):JV^HV>+9S=<L]:GF*\9-P$]#R"+AA*P\M'.5$'+=8ATED
MCF(8HE$0]!06"<1\=\KS4[8^:>7<%P.>M$6A"628R#*Z9GLC/Q#9V5\VC)AW
M5H>,6D63=Z0%4TU1.4BG^P``B/H(WT[X]N(.SW,7(]3<M8OM\U"-/Z^'LMWI
M46]MT9'?L.M_6,;>V2:6=M%@LH8_\8CL$/F83?#W$1]!)^:^*>1^.HJ1AN6^
M<<=PAK-%(6=<9O18*NS-@(D8ID26&PM6@3\^1`Q`%,KQRN"8A[E]O0<_WRH1
MLCY!_M:X9@2;&2F:%EVI\NXM(J?PG*T<-0SQ!EN6P($$2BV`C5:P3Z"H^X`)
MD1]_\>@WD=(\2?C,V#8)'?-/X<YNO&N34J$]/W&P9I`O7%FG?F112<M449`(
M&T3+A1,#+.I!JY76,'NH<P_GT!ZM*U78^NH5"/@8>/JC2')7FE:81K-C`M(%
M)F$>E"M(EJBDP:Q2+``1(W33*D1(`*!0+^/0#Y@?$_'W*TK8)WFCE_!<"FK9
M'M(FSRV0952\]DK!%L')WC*.F'M7AHQQ(LFKM0RJ:2IC$*H/R`/?\^@\]3X=
MXUH>V272E*Y8P"J="S,K9YV6VZ`R>DQ6JR4U=DWR-PEGM\9PR5E<R-G1DW)'
MZQW(J.B+J`H)@.8!`F9*-CIF.?P\PP92L3*LG4;*1<DU0?1TE'/D%&KU@_9.
MDU6SQD\;*F3524*9-1,PE,`@(AZ!3<]X&/#O9;BM>I3Q\<]!/.'BC]=&,KLE
M`UA5TLJ*RICT:"EXVDF3.H81%/\`K_U_GV^/M^/0'6XY'Y7=X_%\^.><,,6P
MB%?Q4M$XT?*Z0.7QTK!O$I&(E&E%_I/^M(R4=(($727!M^TBQ0.!OE^?07K+
M1$3/Q,E`SL7'34',Q[R)F(:69-I&)E8J0;J-'\9)1SQ)9F^CWS14Z2R*I#IJ
MIF$I@$!$/0+!C?"#XC8F_%TMCX]N8D[621++)?NSJ/>5E"0(O_*3<-Z&\,XH
MC<4W'^Y2DC2D*(![`'L'H&42]*I\_39/.IJKP$I09JLO:7+4M[$L5ZM(U"1B
ME(-]5W<$=`8U:`=PRQFBC04_T&;F%,2_#\>@C&/XKD'/E!B,KPK,*%CV:0"\
MFYA*#FE5A:74(EQ-23J8EUX^OU]FPBVBTG*O5G*YB)`9594QS")A$?080_.'
M/ZFWI=+J8KERG0Z%:&F(;@I1ZZ?54*D**C<:TC>S1XV1&#%!8Y!:E<`B)3F#
'X^QA]P__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
